NEW DRUG APPROVAL: The U.S. Food & Drug Administration (FDA) has granted Portola Pharmaceuticals approval to market Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote indicated to reverse the anticoagulation effects of factor Xa inhibitors, such as Xarelto® (rivaroxaban) and Eliquis® (apixaban), when patients are experiencing uncontrolled or life-threatening bleeding.
This is important news for nearly four million people who are prescribed these medications. Read more about this news from Medscape here, and also read the press release distributed by Portola in light of this FDA approval here.
Talk to your healthcare provider if you have questions about this new reversal agent or any medications you may be taking.
Learn more about the treatment options for blood clots here.
